BrickellBio
View On Demand

Rebalancing The Immune System To Treat Autoimmune Diseases

About the Event


Brickell Biotech is a development stage pharmaceutical company with a robust pipeline of treatments for a variety of debilitating diseases, including rheumatoid arthritis, atopic dermatitis, and other autoimmune conditions. 

BrickellBio’s lead asset is an orally-available, phase-one ready DYRK1A inhibitor. It has a dual mode of action to restore regulatory T-cell homeostasis while inhibiting MyD88/IRAK4 signaling pathways. In addition, the company’s portfolio of next generation compounds could lead to viable treatments for other indications including neuroinflammatory and rare orphan diseases.

Join this webinar to hear from the BrickellBio leadership team which has launched some of the most successful drugs on the market today including Cialis, Prozac, Cymbalta, Juvederm, and more.

View On-Demand Webinar


SHARE THIS EVENT
Share on facebook
Share on twitter
Share on linkedin

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.